Developing Assays for Novel Drugs

Current science regarding hybrid assays, why they are considered the next "big thing," the technical challenges, and the regulatory impact of these assays.

Novel drugs with complex design are becoming more common to treat difficult diseases.

This insight brief, authored by Michael Brown, Ph.D., Senior Director, Immunoanalytical Services and Barry Jones, Ph.D., Director, LC-MS Biologics and Biomarkers, provides an overview of the development of assays for these novel drugs including where the field may be moving in the future.

Complete the form below to access this insight brief